Eisai, Inc._E2086-G000-202_140993-01_Narcolepsy (140993-01)
-
- STATUS
- Recruiting
-
- sponsor
- Eisai, Inc.
Summary
To identify the optimal doses of E2086 compared to placebo in subjects with narcolepsy for reduction of excessive daytime sleepiness (EDS) as assessed by Mean Sleep Latency (MSL)
Description
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of E2086 in Adults with Narcolepsy. Multicenter, global at approximately 65 sites in North America, Europe, and Asia. Two cohorts for NT1 & NT2. 320 screened to provide 64 randomized subjects. 32 subjects with NT1 and approximately 32 subjects with NT2.
Details
| Condition | Narcolepsy; Excessive daytime sleepiness (EDS) as assessed by Mean Sleep Latency (MSL); Weekly Cataplexy Rate (WCR) |
|---|---|
| Age | 18years or above |
| Clinical Study Identifier | Eisai, Inc. |
| Sponsor | Eisai, Inc. |
| Last Modified on | 24 June 2026 |
Eligibility
How to participate?
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.